Credit Suisse Starts Overstock.com (OSTK) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Stocks with Implied Volatility Movement
September 16, 2020 3:59 AM EDTOverstock.com (NASDAQ: OSTK) implied volatility has had increased movement
... MoreWedbush Starts Overstock.com (OSTK) at Outperform
September 15, 2020 4:12 PM EDTWedbush initiates coverage on Overstock.com (NASDAQ: OSTK) with a Outperform rating.
For an analyst ratings summary and ratings history on Overstock.com click here. For more ratings news on Overstock.com click here.
Shares of Overstock.com closed at $75.73 yesterday.
... MoreOverstock.com (OSTK) Investor Meeting Indicates Q3 Trends Remain Strong - Piper Sandler
September 15, 2020 8:07 AM EDTPiper Sandler analyst Peter Keith reiterated an Overweight rating and $140.00 price target on Overstock.com (NASDAQ: OSTK) after hosting a virtual investor meeting with Overstock CEO, Jonathan Johnson and CFO, Adrianne Lee.
The analyst stated "Q3 trends appear to be continuing... More
Pre-Open Stock Movers 09/14: (IMMU) (SGMS) (NVDA) Higher; (GILD) (MGM) (WMT) Lower (more...)
September 14, 2020 9:30 AM EDTPre-Open Stock Movers
Cassava Sciences, Inc. (Nasdaq: SAVA) 117% HIGHER; announced final results of a Phase 2b study with its lead drug candidate, sumifilam, in Alzheimers disease. In a clinical study funded by the National Institutes of Health (NIH), sumifilam significantly improved an entire panel of validated biomarkers of disease in patients with Alzheimers disease. The ability to improve multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimers disease. Study results are expected to be published in a... More
Needham & Company Starts Overstock.com (OSTK) at Buy; 'Home is Where the Growth Is'
September 14, 2020 5:17 AM EDT(Updated - September 14, 2020 5:20 AM EDT)
(updating comment)
Needham & Company analyst Rick Patel initiates coverage on Overstock.com (NASDAQ: OSTK) with a Buy rating and $96 price target.
The analyst comments "In our view, Overstock is benefiting from external and internal factors... More

